{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Torres M"],"funding":["Instituto de Salud Carlos III","NIAID NIH HHS","España Ministerio de Ciencia e Innovación"],"pagination":["112965"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9008199"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["150"],"pubmed_abstract":["Main cause of severe illness and death in COVID-19 patients appears to be an excessive but ineffectual inflammatory immune response that may cause severe acute respiratory distress syndrome (ARDS). Vitamin D may favour an anti-inflammatory environment and improve cytotoxic response against some infectious diseases. A multicenter, single-blind, prospective, randomized clinical trial was approved in patients with COVID-19 pneumonia and levels of 25-hydroxyvitamin D (25(OH)D) of 14.8 ng/ml (SD: 6.18) to test antiviral efficacy, tolerance and safety of 10,000 IU/day of cholecalciferol (vitamin D<sub>3</sub>) for 14 days, in comparison with 2000 IU/day. After supplementation, mean serum 25(OH)D levels increased to 19 ng/ml on average in 2000 IU/day versus 29 ng/ml in 10,000 IU/day group (p < 0."],"journal":["Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie"],"pubmed_title":["Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D."],"pmcid":["PMC9008199"],"funding_grant_id":["R01 AI143567"],"pubmed_authors":["Mateos E","Taboada-Martinez ML","Patricia Fernandez Fernandez C","Pardo Guimera V","Jose Martinez Martin E","Contributing members of the Multidisciplinary Group of Study of COVID-19 (in alphabetical order)","Garcia Lacalle C","Multidisciplinary Group of Study of COVID-19 (MGS-COVID)","Cascajero Diaz A","Carrillo Blanco G","Martin Sagarra O","Renuncio Garcia D","Ramos-Martin F","Torres Perea R","Javier Martinez Simon J","Sanz-Moreno J","Teresa Chica Burguillo M","Diez Vinas V","Arevalo Camacho S","Sanz Moreno J","Lopez-Wolf D","Rodriguez-Mora S","Fernandez Mondelo Y","Lucena Campillo A","Luisa Pinillos Pardo M","Velasco Arribas M","Valencia La Rosa J","Corrochano Garcia A","Torres M","Alonso-Menchen D","Blanca Lopez N","Fonseca Aizpuri E","Garcia-Perez J","Roger Revilla A","Matarranz Del Amo M","Casado G","Lopez-Huertas MR","Helguera Amezua C","Gomez-Alvarez Dominguez M","Novella-Mena M","Vigon L","Ryan-Murua P","Angeles Rodriguez Davila M","Sampablo Valverde L","Canamares Orbis I","Ramirez Fuentes FA","Cervero M","Jose Hidalgo Correas F","Villanueva Fernandez-Ardavin A","Coiras M","Corredera Garcia S","Avila Calzada C","Antonio Barbado Albaladejo J"],"additional_accession":[]},"is_claimable":false,"name":"Changes in the immune response against SARS-CoV-2 in individuals with severe COVID-19 treated with high dose of vitamin D.","description":"Main cause of severe illness and death in COVID-19 patients appears to be an excessive but ineffectual inflammatory immune response that may cause severe acute respiratory distress syndrome (ARDS). Vitamin D may favour an anti-inflammatory environment and improve cytotoxic response against some infectious diseases. A multicenter, single-blind, prospective, randomized clinical trial was approved in patients with COVID-19 pneumonia and levels of 25-hydroxyvitamin D (25(OH)D) of 14.8 ng/ml (SD: 6.18) to test antiviral efficacy, tolerance and safety of 10,000 IU/day of cholecalciferol (vitamin D<sub>3</sub>) for 14 days, in comparison with 2000 IU/day. After supplementation, mean serum 25(OH)D levels increased to 19 ng/ml on average in 2000 IU/day versus 29 ng/ml in 10,000 IU/day group (p < 0.","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jun","modification":"2025-05-18T10:52:48.89Z","creation":"2024-10-17T18:32:02.461Z"},"accession":"S-EPMC9008199","cross_references":{"pubmed":["35468580"],"doi":["10.1016/j.biopha.2022.112965"]}}